Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010

Alzheimer's and Dementia

Volumn 10, Issue 3, 2014, Pages 310-318

  Zilkens, Renate R ^a   Duke, Janine ^a,b   Horner, Barbara ^c   Semmens, James B ^a   Bruce, David G ^d  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Age specific rates; Alzheimer's disease; Cholinesterase inhibitors; Drug prescriptions; Epidemiology; Remoteness; Retrospective studies; Socioeconomic disadvantage

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUSTRALIA; FEMALE; GEOGRAPHY; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HUMAN; MALE; PRESCRIPTION; PRIORITY JOURNAL; SOCIOECONOMICS; VERY ELDERLY; AGE; CLINICAL PRACTICE; COHORT ANALYSIS; EPIDEMIOLOGY; MIDDLE AGED; RURAL POPULATION; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TRENDS; URBAN POPULATION; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AUSTRALIA; CHOLINESTERASE INHIBITORS; COHORT STUDIES; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS; RURAL POPULATION; SEX FACTORS; SOCIOECONOMIC FACTORS; URBAN POPULATION; YOUNG ADULT;

EID: 84899618063     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.04.001     Document Type: Article

References (45)

1. Alzheimer's Disease International. World Alzheimer's report.London. Available at: http://www.alz.co.uk/research/files/WorldAlzheimerReport. pdf. Accessed February 20, 2013.
2. Access Economics. Dementia estimates and projections: Australian states and territories. Report for Alzheimer's Australia WA Canberra Access Economics Pty Ltd. 2005. Available at: www. alzheimers.org.au. Accessed November 15, 2012.
3. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004;12:358-69.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593.
5. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-Year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21:353-63.
6. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:893-903.
7. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009; 24:479-88.
8. Grossberg GT. Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings. Drugs Aging 2008;25:573-84.
9. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363:2105-15.
10. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331:321-7.
11. Wallin AK, Gustafson L, Sjogren M,Wattmo C, Minthon L. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord 2004; 18:197-206.
12. Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother 2005;3:1-7.
13. Rickard M. The Pharmaceutical Benefits Scheme: options for cost control. Current issues brief no. 12 2001-02. Canberra Social Policy Group, Parliamentary Library. Available at: http://www.aph.gov.au/ About-Parliament/Parliamentary- Departments/Parliamentary-Library/ Publications-Archive/CIB/cib0102/02CIB12. Accessed February 20, 2013.
14. Department of Health and Ageing. October 2012. History of PBS copayments and Safety Net thresholds. Available at: http://www.health.gov.au/internet/main/ publishing.nsf/Content/ health-pbs-general-pbs-copayment.htm. Accessed February 20, 2013.
15. The Royal Australasian College of Physicians and the Australian and New Zealand Society for Geriatric Medicine. House Standing Committee on Health and Ageing inquiry into dementia: early diagnosis and intervention 2012. p. 1-27 .Available at: http://www.aph.gov.au/ Parliamentary-Business/Committees/House- of-Representatives-Co mmittees?url=haa/dementia/subs.htm. Accessed October 16, 2012.
16. Woodward MC,Woodward E. A national survey of memory clinics in Australia. Int Psychogeriatr 2009;21:696-702.
17. Speechly CM, Bridges-Webb C, Passmore E. The pathway to dementia diagnosis. Med J Austr 2008;189:487-9.
18. Hansen E, Robinson A, Mudge P, Crack G. Barriers to the provision of care for people with dementia and their carers in a rural community. Austr J Primary Health 2005;11:72-9.
19. Yeoh R. Speech by President of Dementia Awareness Week given at launch of Dementia Awareness Week, September 16, 2002. Available at: http://www. fightdementia.org.au/research-publications/speeches. aspx2002. Accessed February 21, 2013.
20. National Institute for Health Care Management. Prescription drugs and massmedia advertising. Research brief.Washington, DC:NIHCMFoundation; 2000. Available at: http://www.nihcm.org/pdf/DTCbrief.pdf.
21. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15.
22. Access Economics. The dementia epidemic: economic impact and positive solutions for Australia. Report for Alzheimer's Australia WA Canberra Access Economics Pty Limited. 2003. Available at: www.alzheimers.org.au. Accessed August 20, 2012.
23. Hollingworth SA, Byrne GJ. Prescribing trends in cognition enhancing drugs in Australia. Int Psychogeriatr 2011;23:238-45.
24. Department of Health and Ageing. 2008. Impact of the collection and recording of PBS under co-payment prescription data. Final report Department of Health and Ageing, Adelaide. Available at: http://www.health.gov.au/internet/ main/publishing.nsf/content/ 3afdb28cdc5c43a5ca25751400032d03/$file/ pbs%20under%20co-pay %20report.pdf. Accessed February 20, 2013.
25. Glover J, Tennant S. Remote areas statistical geography in Australia: notes on the accessibility/remoteness index for Australia (ARIA1version). Working papers series no. 9. Adelaide Public Health Information Development Unit. Available at: http://www.publichealth.gov.au/ publications/remote-areas- statistical-geography-in-australia%3A-not es-on-the-accessibility%10remoteness- index-for-australia-%5Bariaversion% 5D.html. Accessed May 15, 2012.
26. AustralianBureau ofStatistics. Socioeconomic indexes for areas (SEIFA). Technical paper. Catalogue no. 2039.0.55.001. Canberra: ABS; 2006.
27. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Group. Neurology 2000;54:S4-9.
28. Franchi C, Lucca U, Tettamanti M, Riva E, Fortino I, Bortolotti A, et al. Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARMElderly Project. Pharmacoepidemiol Drug Saf 2011;20:497-505.
29. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Services 2004;34:101-22.
30. Doran E, Robertson J, Rolfe I, Henry D. Patient co-payments and use of prescription medicines. Austr N Z J Public Health 2004;28:62-7.
31. Hynd A, Roughead EE, Preen DB, Glover J, BulsaraM, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 2008;17:1091-9.
32. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.
33. Hoffmann F, van den Bussche H, Wiese B, Schon G, Koller D, Eisele M, et al. Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Psychiatry 2011;11:190.
34. Luscombe G, Brodaty H, Freeth S. Younger people with dementia: diagnostic issues, effects on carers and use of services. Int J Geriatr Psychiatry 1998;13:323-30.
35. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012;8:131-68.
36. Cooper C, Blanchard M, Selwood A, Livingston G. Antidementia drugs: prescription by level of cognitive impairment or by socioeconomic group? Aging Mental Health 2010; 14:85-9.
37. Johnell K, Weitoft GR, Fastbom J. Education and use of dementia drugs: a register-based study of over 600,000 older people. Dement Geriatr Cogn Disord 2008;25:54-9.
38. Matthews FE, McKeith I, Bond J, Brayne C. Reaching the population with dementia drugs: what are the challenges? Int J Geriatr Psychiatry 2007;22:627-31.
39. Amuah JE, Hogan DB, Eliasziw M, Supina A, Beck P, Downey W, et al. Persistence with cholinesterase inhibitor therapy in a population- based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf 2010;19:670-9.
40. Willems S, de Maesschalck S, Deveugele M, Derese A, de Maeseneer J. Socioeconomic status of the patient and doctor-patient communication: does it make a difference? Patient Educ Couns 2005;56:139-46.
41. Australian Institute of Health and Welfare. Health in rural and remote Australia. AIHW catalogue no. PHE 6. Canberra: Australian Institute to Health and Welfare; 1998.
42. Calver J, Preen D, Bulsara M, Sanfilippo F. Stimulant prescribing for the treatment of ADHD in western Australia: socioeconomic and remoteness differences. Med J Austr 2007;186:124-7.
43. Goldney RD, Taylor AW, Bain MA. Depression and remoteness from health services in South Australia. Austr J Rural Health 2007; 15:201-10.
44. Pharmaceutical Benefits Advisory Committee. July 2011 PBAC meeting outcomes: positive recommendations. Canberra: Department of Health and Ageing; 2011.
45. NPS Radar. Drugs for Alzheimer's disease: PBS criteria no longer include referral to a specialist. 2011. Available at: http://www.nps.org. au/publications/health-professional/nps-radar/2011/november-2011/ brief-item-alzheimers-change-listing. Accessed October 26, 2012.